Exelixis: Zanzalintinib MOA Overcomes Competing CRC Regorafenib Treatment
Core Insights - Exelixis has made significant advancements in its pipeline due to two recent key developments [2] Group 1: Company Developments - Exelixis' partner Ipsen received a positive opinion from the European Medicines Agency, which is a crucial step for the company's product pipeline [2]